{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:59Z","timestamp":1791650579428,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcjo.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:19:23Z","timestamp":1781219963000},"page":"1262-1271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetic macular edema and GLP-1 receptor agonist use: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"61","author":[{"given":"Salem Abu","family":"Al-Burak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6501-6196","authenticated-orcid":false,"given":"Vitaliy","family":"Voznyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouad","family":"Elganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-6497","authenticated-orcid":false,"given":"Chris","family":"Zajner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Juncal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-1857","authenticated-orcid":false,"given":"Thomas G.","family":"Sheidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monali S.","family":"Malvankar-Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/joco.joco_133_24","article-title":"Persistent diabetic macular edema: a comprehensive review of current treatments and emerging therapeutic options","volume":"36","author":"Faghihi","year":"2024","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4239\/wjd.v2.i6.98","article-title":"Managing diabetic macular edema: the leading cause of diabetes blindness","volume":"2","author":"Romero-Aroca","year":"2011","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101406","article-title":"International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME)","volume":"109","author":"Ng","year":"2025","journal-title":"Prog Retinal Eye Res"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105115","article-title":"Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy","volume":"161","author":"Rudraraju","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/aos.16675","article-title":"The incidence and prevalence of diabetic macular edema and proliferative diabetic retinopathy, their progression to visual impairment and patterns in their intravitreal treatment in the Finnish population","volume":"102","author":"Heloter\u00e4","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0008","article-title":"Prevalence and associated risk factors of diabetic retinopathy and macular oedema in patients recently diagnosed with type 2 diabetes","volume":"5","author":"EO","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.33590\/emjdiabet\/10311312","article-title":"Who gets diabetic macular oedema; when; and why? Pathogenesis and risk factors","volume":"2","author":"Turgut Ozturk","year":"2014","journal-title":"EMJ Diabet"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ehjcvp\/pvaf037","article-title":"Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"11","author":"Kalayci","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0011","series-title":"StatPearls","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins","year":"2025"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with Type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4239\/wjd.v14.i4.424","article-title":"Semaglutide-eye-catching results","volume":"14","author":"Cigrovski Berkovic","year":"2023","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/IAE.0000000000004507","article-title":"Real-world associations between GLP-1 receptor agonist use and diabetic retinopathy accounting for longitudinal glycemic control","volume":"45","author":"Talebi","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes\u2014A systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0022","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0024","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy","volume":"8","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108808","article-title":"Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema","volume":"38","author":"Phu","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0026","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3928\/23258160-20230217-02","article-title":"Evaluating the effect of hypoglycemic agents on diabetic retinopathy progression","volume":"54","author":"Wai","year":"2023","journal-title":"Ophthal Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/09286586.2024.2399764","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with an increased risk of progressing to vision-threatening diabetic retinopathy","volume":"32","author":"Tauqeer","year":"2025","journal-title":"Ophthal Epidemiol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.oret.2024.12.006","article-title":"Influence of common medications on diabetic macular edema in type 2 diabetes mellitus","volume":"9","author":"Muayad","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/cpt.70087","article-title":"Ocular complications of SGLT -2 inhibitors, GLP -1 receptor agonists, and DPP-4 inhibitors in T2DM treatments: a retrospective real-world cohort study","volume":"119","author":"Lin","year":"2026","journal-title":"Clin Pharma Ther"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0031","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/dom.14445","article-title":"Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan","volume":"23","author":"Su","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0032","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium\u2013glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.oret.2025.07.019","article-title":"Risk of sight-threatening diabetic retinopathy with glucagon-like peptide-1 receptor agonist use in routine clinical practice","volume":"10","author":"Barkmeier","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcjd.2025.07.002","article-title":"In the eye of controversy: a deeper look into the impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy","volume":"49","author":"Nadeem","year":"2025","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0035","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.diabres.2013.12.041","article-title":"The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy","volume":"103","author":"Varadhan","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the diabetes control and complications trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0038","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0039","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2025-005424","article-title":"Semaglutide and diabetic retinopathy: an OHDSI network study","volume":"13","author":"Cai","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0041","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/jdi.14229","article-title":"A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data","volume":"15","author":"Du","year":"2024","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108631","article-title":"Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors","volume":"38","author":"Xu","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-002801","article-title":"Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes","volume":"10","author":"Luo","year":"2022","journal-title":"BMJ Open Diab Res Care"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0044","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1210\/clinem\/dgab050","article-title":"SGLT2 inhibitor\u2013induced low-grade ketonemia ameliorates retinal hypoxia in diabetic retinopathy\u2014a novel hypothesis","volume":"106","author":"Mudaliar","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjo.2026.05.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8867875","article-title":"The role of SGLT2 inhibitor on the treatment of diabetic retinopathy","volume":"2020","author":"Sha","year":"2020","journal-title":"J Diabetes Res"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226002061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226002061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:26:25Z","timestamp":1788582385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226002061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0008418226002061"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.05.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic macular edema and GLP-1 receptor agonist use: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}